Evolving Paradigms in the Management of Primary Immune Thrombocytopenia in Adults: From Corticosteroids to Targeted Therapies. (PubMed, Mediterr J Hematol Infect Dis) - Sep 13, 2026 - "For decades, treatment relied on corticosteroids as first-line therapy, followed by a limited range of second-line options including thrombopoietin receptor agonists (TPO-RAs), rituximab, splenectomy, and, more recently, fostamatinib. Particular attention is given to distinguishing approved therapies from investigational agents by region and date, interpreting heterogeneous trial endpoints with appropriate caution, and integrating disease features, safety considerations, and patient preferences into treatment selection. Although recent phase II and III studies support the biological and clinical promise of several targeted agents, the optimal sequencing and combination of these therapies remain to be defined."
Journal • Review • Fatigue • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura • BTK
|
|
Caterina Alati; Laura Giordano; Maria Bruna Greve; Massimo Martino; Violetta Marafioti
|